Cargando…

Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies

Cutaneous adverse drug reactions are commonly seen in patients with anticancer drug treatment. Anticancer drugs, including chemotherapy, target therapy, and recent immunotherapy causing skin reactions ranging from mild skin rash to life-threatening severe cutaneous adverse reactions (SCARs), such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Chau Yee, Chen, Chun-Bing, Wu, Ming-Ying, Wu, Jennifer, Yang, Chih-Hsun, Hui, Rosaline Chung-Yee, Chang, Ya-Ching, Lu, Chun-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5822766/
https://www.ncbi.nlm.nih.gov/pubmed/29577050
http://dx.doi.org/10.1155/2018/5376476
_version_ 1783301747877347328
author Ng, Chau Yee
Chen, Chun-Bing
Wu, Ming-Ying
Wu, Jennifer
Yang, Chih-Hsun
Hui, Rosaline Chung-Yee
Chang, Ya-Ching
Lu, Chun-Wei
author_facet Ng, Chau Yee
Chen, Chun-Bing
Wu, Ming-Ying
Wu, Jennifer
Yang, Chih-Hsun
Hui, Rosaline Chung-Yee
Chang, Ya-Ching
Lu, Chun-Wei
author_sort Ng, Chau Yee
collection PubMed
description Cutaneous adverse drug reactions are commonly seen in patients with anticancer drug treatment. Anticancer drugs, including chemotherapy, target therapy, and recent immunotherapy causing skin reactions ranging from mild skin rash to life-threatening severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN) with increase morbidity and mortality while they are receiving cancer treatments, have been proposed to be a result of direct skin toxicity or drug hypersensitivity reactions (these are proposed mechanism, not definite). Differentiating SCARs from other more commonly seen reactions with a better outcome help prevent discontinuation of therapy and inappropriate use of systemic immunosuppressants for presumable allergic reactions, of which will affect the clinical outcome. In this article, we have reviewed published articles from 1950 to August 2017 for SJS/TEN associated with anticancer drugs, including chemotherapy, targeted therapy, and immunotherapy. We aimed to provide an overview of SJS/TEN associated with anticancer drugs to increase clinician recognition and accelerate future studies on the pathomechanism and managements.
format Online
Article
Text
id pubmed-5822766
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-58227662018-03-25 Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies Ng, Chau Yee Chen, Chun-Bing Wu, Ming-Ying Wu, Jennifer Yang, Chih-Hsun Hui, Rosaline Chung-Yee Chang, Ya-Ching Lu, Chun-Wei J Immunol Res Review Article Cutaneous adverse drug reactions are commonly seen in patients with anticancer drug treatment. Anticancer drugs, including chemotherapy, target therapy, and recent immunotherapy causing skin reactions ranging from mild skin rash to life-threatening severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN) with increase morbidity and mortality while they are receiving cancer treatments, have been proposed to be a result of direct skin toxicity or drug hypersensitivity reactions (these are proposed mechanism, not definite). Differentiating SCARs from other more commonly seen reactions with a better outcome help prevent discontinuation of therapy and inappropriate use of systemic immunosuppressants for presumable allergic reactions, of which will affect the clinical outcome. In this article, we have reviewed published articles from 1950 to August 2017 for SJS/TEN associated with anticancer drugs, including chemotherapy, targeted therapy, and immunotherapy. We aimed to provide an overview of SJS/TEN associated with anticancer drugs to increase clinician recognition and accelerate future studies on the pathomechanism and managements. Hindawi 2018-01-17 /pmc/articles/PMC5822766/ /pubmed/29577050 http://dx.doi.org/10.1155/2018/5376476 Text en Copyright © 2018 Chau Yee Ng et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Ng, Chau Yee
Chen, Chun-Bing
Wu, Ming-Ying
Wu, Jennifer
Yang, Chih-Hsun
Hui, Rosaline Chung-Yee
Chang, Ya-Ching
Lu, Chun-Wei
Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies
title Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies
title_full Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies
title_fullStr Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies
title_full_unstemmed Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies
title_short Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies
title_sort anticancer drugs induced severe adverse cutaneous drug reactions: an updated review on the risks associated with anticancer targeted therapy or immunotherapies
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5822766/
https://www.ncbi.nlm.nih.gov/pubmed/29577050
http://dx.doi.org/10.1155/2018/5376476
work_keys_str_mv AT ngchauyee anticancerdrugsinducedsevereadversecutaneousdrugreactionsanupdatedreviewontherisksassociatedwithanticancertargetedtherapyorimmunotherapies
AT chenchunbing anticancerdrugsinducedsevereadversecutaneousdrugreactionsanupdatedreviewontherisksassociatedwithanticancertargetedtherapyorimmunotherapies
AT wumingying anticancerdrugsinducedsevereadversecutaneousdrugreactionsanupdatedreviewontherisksassociatedwithanticancertargetedtherapyorimmunotherapies
AT wujennifer anticancerdrugsinducedsevereadversecutaneousdrugreactionsanupdatedreviewontherisksassociatedwithanticancertargetedtherapyorimmunotherapies
AT yangchihhsun anticancerdrugsinducedsevereadversecutaneousdrugreactionsanupdatedreviewontherisksassociatedwithanticancertargetedtherapyorimmunotherapies
AT huirosalinechungyee anticancerdrugsinducedsevereadversecutaneousdrugreactionsanupdatedreviewontherisksassociatedwithanticancertargetedtherapyorimmunotherapies
AT changyaching anticancerdrugsinducedsevereadversecutaneousdrugreactionsanupdatedreviewontherisksassociatedwithanticancertargetedtherapyorimmunotherapies
AT luchunwei anticancerdrugsinducedsevereadversecutaneousdrugreactionsanupdatedreviewontherisksassociatedwithanticancertargetedtherapyorimmunotherapies